Verastem Stock Forecast, Price & News

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Verastem in the last year. There are currently 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Verastem stock.
View analyst ratings for Verastem or view top-rated stocks.

5 analysts have issued 1 year price objectives for Verastem's stock. Their VSTM stock forecasts range from $5.00 to $6.00. On average, they expect Verastem's stock price to reach $5.50 in the next year. This suggests a possible upside of 358.3% from the stock's current price.
View analysts' price targets for Verastem or view top-rated stocks among Wall Street analysts.

Verastem's stock was trading at $2.05 at the beginning of the year. Since then, VSTM stock has decreased by 41.5% and is now trading at $1.20.
View the best growth stocks for 2022 here.

Verastem is scheduled to release its next quarterly earnings announcement on Monday, August 1st 2022.
View our earnings forecast for Verastem.

Verastem, Inc. (NASDAQ:VSTM) announced its earnings results on Monday, May, 9th. The biopharmaceutical company reported ($0.09) EPS for the quarter, missing the consensus estimate of ($0.08) by $0.01. The biopharmaceutical company had revenue of $2.60 million for the quarter, compared to analyst estimates of $2.50 million. Verastem had a negative trailing twelve-month return on equity of 84.99% and a negative net margin of 2,007.44%.
View Verastem's earnings history.

11 employees have rated Verastem CEO Robert Forrester on Glassdoor.com. Robert Forrester has an approval rating of 100% among Verastem's employees. This puts Robert Forrester in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Some companies that are related to Verastem include Amgen (AMGN), Gilead Sciences (GILD), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Seagen (SGEN), Biogen (BIIB), Alnylam Pharmaceuticals (ALNY), Incyte (INCY), BioMarin Pharmaceutical (BMRN), United Therapeutics (UTHR), Neurocrine Biosciences (NBIX), Repligen (RGEN), Exact Sciences (EXAS), Exelixis (EXEL) and Halozyme Therapeutics (HALO).
View all of VSTM's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Verastem investors own include TherapeuticsMD (TXMD), Micron Technology (MU), Novavax (NVAX), Inovio Pharmaceuticals (INO), Gilead Sciences (gild), Sorrento Therapeutics (SRNE), SCYNEXIS (SCYX), TG Therapeutics (TGTX), Amarin (AMRN) and Viking Therapeutics (VKTX).

Verastem trades on the NASDAQ under the ticker symbol "VSTM."

Verastem's stock is owned by a variety of retail and institutional investors. Top institutional investors include BlackRock Inc. (6.54%), Vanguard Group Inc. (4.72%), Eagle Asset Management Inc. (2.48%), State Street Corp (1.67%), Dimensional Fund Advisors LP (1.00%) and Renaissance Technologies LLC (0.90%). Company insiders that own Verastem stock include Brian M Stuglik, Dan Paterson, Ra Capital Management, LP, Robert E Gagnon and Timothy J Barberich.
View institutional ownership trends for Verastem.

VSTM stock was sold by a variety of institutional investors in the last quarter, including State Street Corp, Panagora Asset Management Inc., Dimensional Fund Advisors LP, Bank of America Corp DE, UBS Group AG, Acadian Asset Management LLC, ClariVest Asset Management LLC, and Raymond James & Associates. Company insiders that have sold Verastem company stock in the last two years include Brian M Stuglik, Dan Paterson, and Robert E Gagnon.
View insider buying and selling activity for Verastem or view top insider-selling stocks.

VSTM stock was bought by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Eagle Asset Management Inc., Ergoteles LLC, Wetherby Asset Management Inc., Goldman Sachs Group Inc., Hsbc Holdings PLC, Samalin Investment Counsel LLC, and XTX Topco Ltd.
View insider buying and selling activity for Verastem or or view top insider-buying stocks.

Shares of VSTM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of VSTM stock can currently be purchased for approximately $1.20.

Verastem (NASDAQ:VSTM) has a market capitalization of $223.63 million and generates $2.05 million in revenue each year. The biopharmaceutical company earns $-71.20 million in net income (profit) each year or ($0.41) on an earnings per share basis.

Verastem employs 48 workers across the globe.

Verastem's mailing address is 117 KENDRICK STREET SUITE 500, NEEDHAM MA, 02494. The official website for Verastem is www.verastem.com. The biopharmaceutical company can be reached via phone at (781) 292-4200 or via email at [email protected].